Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease
Status:
RECRUITING
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This trials aims to assess, in 240 eligible patients with coronary heart disease, the effects on level of high-sensitivity C-reactive protein (hsCRP) changes from baseline to 12 weeks of Xuesaitong Soft Capsules.